GlobalData, the industry analysis specialist, has released its new conference alerts, 3rd World Congress on Controversies in Ophthalmology 2012 Post-Conference Review and Analysis. The conference alert is an essential source of information and analysis on the emerging therapies and new disease management techniques.
The annual symposium of the 3rd World Congress on Controversies in Ophthalmology (COPHy) was held in Istanbul, Turkey from March 22 to 25, 2012. The four-day conference included discussions among chairpersons, speakers and the audience, who examined and presented poster presentations related to the most relevant issues that were raised during the course of 2011 within the field of ophthalmology. This report aims to cover some of the scientific presentations and articles released during the conference.
The report provides complete coverage of conference. Its scope includes -
- Qualitative analysis of the studies and clinical trials presented at the conference and their impact on the key market dynamics and future treatment paradigm.
- review of preand post-conference KOL/analyst comments
- Review of key industry trends and events which are likely to impact and change the dynamics of the concerned disease markets in the long run.
Reasons to buy
The report will serve to facilitate your decision making in the concerned therapy areas. It will allow you to -
- Develop business strategies by understanding the trends and developments that are driving or are expected to drive the market in the concerned disease areas.
- Explore M&A opportunities by identifying key products and market players.
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the market opportunities.
- Make more informed business decisions from the insightful and in-depth analysis of the market and the factors influencing the same.
Table of Contents
1 Table of Contents 3
1.1 List of Tables 3
2 3rd World Congress on Controversies in Ophthalmology - Post-Conference Highlights 4
2.1 Comparison of Effects of Intravitreal Triamcinolone Acetonide and Bevacizumab on Macular and Retinal Nerve Fiber Layer Thickness with Diabetic Macular Edema 4
2.2 Compliance to Treatment with Intravitreal Ranizumab in Patients with Neovascular Age-Related Macular Degeneration 5
2.3 Efficacy of Intravitreal Ranibizumab Injection and Fundus Autofluorescence Changes in Acute Central Serous Chorioretinopathy 5
2.4 Corneal Hysteresis as a Therapeutic Target in Glaucoma 6
2.5 Topical Cyclosporine 0.05 % for the Treatment of Subepithelial Infiltrates Secondary to Adenoviral Keratoconjunctivitis 7
2.6 Sulfasalazine Treatment in Preventing Recurrences of Anterior Uveitis Associated Ankylosing Spondylitis 8
2.7 Ranibizumab Injection Frequency and Visual Outcome in Age-Related Macular Degeneration 9
2.8 Comparing Combination of Photodynamic Therapy and Intravitreal Ranizumab Therapy with IVR Monotherapy on Choroidal Neovascular Membranes 9
2.9 Combined Intravitreal Anti-VEGF with Prompt Scatter Laser in the Management of Proliferative Diabetic Retinopathy 11
2.10 The Effect of Combined Treatment with Bevacizumab and Triamcinolone for Diffuse Diabetic Macular Edema Refractory to Previous Intravitreal Injections 12
2.11 Effect of Brinzolamide 1% and Timolol 0.5% Fixed Combination on Intraocular Pressure after Cataract Surgery with Phacoemulsification 13
2.12 Retrospective Data Collection Study in Patients Receiving Two or More Ozurdex Injections for Macular Edema Secondary to Retinal Vein Occlusion 13
2.13 Additive Intraocular Pressure Reducing the Effect of Latanoprost in Patients Insufficiently Controlled on Timolol-Dorzolamide Fixed Combination 14
2.14 Abbreviations 15
2.15 Disclaimer 16
List of Table
Table 1: Effect of Intravitreal Triamcinolone Acetonide and Bevacizumab on Diabetic Macular Edema Patients 4
Table 2: Efficacy Results for Intravitreal Ranibizumab Injection and Fundus Autofluorescence Changes in Acute Central Serous Chorioretinopathy 6
Table 3: Yearly Attack Frequency of Anterior Uveitis Before and After Sulfasalazine Treatment 8
Table 4: Effect of Combination of Photodynamic Therapy and IVR vs IVR Monotherapy on Patients with CNVM 10
Table 5: Effect on OCT Macula Thickness of Combination of PDT and IVR with IVR Monotherapy on CNVM 10
Table 6: Change in BCVA in Patients for a Mean Reinjection Time Receiving Two or More Ozurdex Injections for Macular Edema Secondary to RVO 14
Make an enquiry before buying this Report
Please fill the enquiry form below.